Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Hideaki Nakaya"'
Autor:
Shintaro Yamaguchi, Junichiro Irie, Masanori Mitsuishi, Yuichi Uchino, Hideaki Nakaya, Ryo Takemura, Emi Inagaki, Shotaro Kosugi, Hideyuki Okano, Masato Yasui, Kazuo Tsubota, Kaori Hayashi, Jun Yoshino, Hiroshi Itoh
Publikováno v:
Endocrine Journal, Vol 71, Iss 2, Pp 153-169 (2024)
Obesity and aging are major risk factors for several life-threatening diseases. Accumulating evidence from both rodents and humans suggests that the levels of nicotinamide adenine dinucleotide (NAD+), a regulator of many biological processes, decline
Externí odkaz:
https://doaj.org/article/92235c5b076e4e6488506b52c2421753
Autor:
Masaki Ryuzaki, Hirobumi Tokuyama, Kiyotaka Uchiyama, Hideaki Nakaya, Kazuhiro Hasegawa, Kazutoshi Miyashita, Kohnosuke Konishi, Akinori Hashiguchi, Shu Wakino, Hiroshi Itoh
Publikováno v:
Clinical Medicine Insights: Case Reports, Vol 12 (2019)
Clinical application of immune checkpoint inhibitors (CPIs) including nivolumab is expanding in the field of oncology treatment. Nivolumab is an anti-programmed death 1 protein (PD-1) antibody designed to augment an immunologic reaction against cance
Externí odkaz:
https://doaj.org/article/78b013f2959541248376ef36a00a00bb
Autor:
Yo-ichi Nabeshima, Masato Yasui, Hiroshi Itoh, Kazuo Tsubota, Takashi Ono, Junichiro Irie, Masanori Mitsuishi, Hideaki Nakaya, Shin-ichiro Imai, Kazuya Yamashita, Hideyuki Okano, Shintaro Yamaguchi, Emi Inagaki, Hideo Yukioka, Shuhei Shigaki, Masataka Fujita
Publikováno v:
Endocrine Journal. 67:153-160
Recent studies have revealed that decline in cellular nicotinamide adenine dinucleotide (NAD+) levels causes aging-related disorders and therapeutic approaches increasing cellular NAD+ prevent these disorders in animal models. The administration of n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7355800fce21e9e2383961788edfea4b
https://doi.org/10.1507/endocrj.ej19-0313
https://doi.org/10.1507/endocrj.ej19-0313
Publikováno v:
Sleep Science and Practice, Vol 7, Iss 1, Pp 1-8 (2023)
Abstract Background The existing screening tools for the detection of moderate and severe obstructive sleep apnea (OSA) are tailored to Western individuals. The aim of this study was to formulate and validate a simple anthropometric tool for OSA scre
Externí odkaz:
https://doaj.org/article/a05bab09d37a441ca92a9453fdfbd84d
Autor:
K. Uchiyama, Hirobumi Tokuyama, Shu Wakino, Kazuhiro Hasegawa, Hiroshi Itoh, Kazutoshi Miyashita, Munekazu Ryuzaki, Hideaki Nakaya
Publikováno v:
Journal of Hypertension. 36:e185-e186
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65fe0238717eaaf52a73f756facf8593
https://doi.org/10.1097/01.hjh.0000539510.74234.61
https://doi.org/10.1097/01.hjh.0000539510.74234.61
Autor:
Hirobumi Tokuyama, Kiyotaka Uchiyama, Masaki Ryuzaki, Kohnosuke Konishi, Hiroshi Itoh, Hideaki Nakaya, Shu Wakino, Kazuhiro Hasegawa, Kazutoshi Miyashita, Akinori Hashiguchi
Publikováno v:
Clinical Medicine Insights. Case Reports
Clinical Medicine Insights: Case Reports, Vol 12 (2019)
Clinical Medicine Insights: Case Reports, Vol 12 (2019)
Clinical application of immune checkpoint inhibitors (CPIs) including nivolumab is expanding in the field of oncology treatment. Nivolumab is an anti-programmed death 1 protein (PD-1) antibody designed to augment an immunologic reaction against cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3898547016b3c4daea327b267c558b45
https://doi.org/10.1177/1179547619853647
https://doi.org/10.1177/1179547619853647
Autor:
Junichiro Irie, Emi Inagaki, Masataka Fujita, Hideaki Nakaya, Masanori Mitsuishi, Shintaro Yamaguchi, Kazuya Yamashita, Shuhei Shigaki, Takashi Ono, Hideo Yukioka, Hideyuki Okano, Yo-ichi Nabeshima, Shin-ichiro Imai, Masato Yasui, Kazuo Tsubota, Hiroshi Itoh
Publikováno v:
Endocrine Journal; 2020, Vol. 67 Issue 2, p153-160, 8p
Autor:
Munekazu Ryuzaki, Masahiro Takeuchi, Hideaki Nakaya, Marohito Murakami, Fumiaki Takahashi, Hiroyuki Sasamura, Yuji Sato, Hiroshi Itoh, Stevo Julius, Naoki Tomotsugu
Publikováno v:
American Journal of Hypertension. 26:1381-1388
BACKGROUND Recently, we reported that transient treatment of genetically hypertensive rats with high-dose angiotensin receptor blocker (ARB) causes regression of established hypertension. In this study, we investigated whether treatment with candesar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aace73b5fd919599715b91b268afd11
https://doi.org/10.1093/ajh/hpt105
https://doi.org/10.1093/ajh/hpt105
Autor:
Kaori Hayashi, Hideaki Nakaya, Hiroyuki Sasamura, Kimiko Ishiguro, Hiroshi Itoh, Takao Saruta
Publikováno v:
Hypertension Research. 32:658-664
Hypertension is a disease which affects over 26.4% of the world adult population, therefore novel approaches to the prevention and treatment of this disease need to be examined. Previous studies from our and other laboratories have shown that treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd5805dceeb380beb9a8cd027fcb7d2d
https://doi.org/10.1038/hr.2009.85
https://doi.org/10.1038/hr.2009.85
Autor:
Jihong Han, Hideaki Nakaya, David P. Hajjar, Antonio M. Gotto, Andrew C. Nicholson, Barbara D. Summers
Publikováno v:
The American Journal of Pathology. 174:2007-2014
Thiazolidinediones, a class of drugs for the treatment of type-2 diabetes, are synthetic ligands for peroxisome proliferator-activated receptor-gamma. They have been demonstrated to possess cardioprotective effects in humans and anti-atherogenic prop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48454264361f697e2d43c9481be82f1b
https://doi.org/10.2353/ajpath.2009.080611
https://doi.org/10.2353/ajpath.2009.080611